As of Dec 6, 2024, the Ligand Pharmaceuticals stock's PE ratio is 47.28. This results from the current EPS of $2.64 and stock price of $124.83. The P/E ratio has an increase of 73% from the past four quarters average of 27.4.
The PE ratio of Ligand Pharmaceuticals has averaged 87.62 over the last ten years. The current PE ratio of 47.28 is 46% below the historical average. Over the past ten years, LGND's PE ratio was at its highest in the Sep 2020 quarter at 794.33, when the stock price was $95.32 and the EPS was $0.12. The lowest value was in the Dec 2019 quarter, when it reached 3.15 with a price of $104.29 and an EPS of $33.13.
Maximum annual decrease: -91.22% in 2018
Year | PE ratio | Change |
---|---|---|
2023 | 23.65 | N/A |
2022 | N/A | N/A |
2021 | 44.9 | N/A |
2020 | N/A | N/A |
2019 | 3.15 | -84.28% |
2018 | 20.04 | -91.22% |
2017 | 228.22 | N/A |
2016 | N/A | N/A |
2015 | 9.34 | -89.64% |
2014 | 90.19 | -3.98% |
The current PE ratio of LGND is greater than its 3-year historical average, but it is below the 5 and 10-year averages.
LGND's PE ratio is lower than its peer stocks LLY and BAX, but it is greater than JNJ's and MRK's. Ligand Pharmaceuticals is presently trading at a higher PE ratio (47.28) than its peer group average of 40.74.
Stock name | PE ratio | Market cap |
---|---|---|
MRK Merck & Co Inc | 21.52 | $260.78B |
JNJ Johnson & Johnson | 24.76 | $359.48B |
PFE Pfizer Inc | 33.86 | $145.81B |
AMGN Amgen Inc | 34.55 | $146.52B |
LGND Ligand Pharmaceuticals Inc | 47.28 | $2.36B |
LLY ELI LILLY & Co | 88.99 | $784.81B |
BAX Baxter International Inc | 151.43 | $16.24B |
BMY Bristol Myers Squibb Co | N/A | $120.43B |
The price to earnings ratio for LGND stock is 47.28 as of Dec 6, 2024.
The 3-year average PE ratio for LGND stock is 43.88.
The 5-year average PE ratio for LGND stock is 95.34.
The highest quarterly PE ratio in the last ten years has been 794.33 and it was in the Sep 2020 quarter.
LGND's price to earnings ratio is currently 46% below its 10-year historical average.
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (Dec 6, 2024), Ligand Pharmaceuticals's stock price is $124.83. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $2.64. Therefore, Ligand Pharmaceuticals's P/E ratio for today is 47.28. PE RATIO(47.28) = STOCK PRICE($124.83) / TTM EPS($2.64)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.